Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with mFOLFIRINOX or GX in Pancreatic Cancer
NCT06389760Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nimotuzumab in pancreatic cancer (PC), sponsored by Nanjing Drum-Tower Hospital. Started Oct 2023; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06389760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389760.